Quick Takeaways
- Matthew Lang has 3 issuer positions tracked on this page.
- Estimated disclosed ownership value: $114,000.
- Recent insider filing activity is available below.
- Info
- Insider Ownership
Insider Trading & Ownership of Matthew Lang
- Location
- Brisbane, CA
- Summary
- The estimated net worth of Matthew Lang is at least $114,000 dollars as of 13 Nov 2025. Matthew Lang is the Chief Business Officer of Lyell Immunopharma, Inc. and owns shares of Lyell Immunopharma, Inc. (LYEL) stock worth about $114K.
- Signature
- /s/ Matthew Lang
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Matthew Lang and return when a new Insider Trading filing appears.
This tracks SEC filing changes for this page using existing product update flows.
What Changed
- Largest disclosed position: Lyell Immunopharma, Inc. ($114,000).
- Past-year value change for that position: .
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Official SEC Source
Filed on Form 4
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
See Original FilingOwnership of Matthew Lang
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| LYEL | Lyell Immunopharma, Inc. | Chief Business Officer | $114,000 | 10 Feb 2025 | ||
| MTSR | Metsera, Inc. | Chief Legal Officer | $0 | 13 Nov 2025 | ||
| MYOV | Myovant Sciences Ltd. | General Counsel & Corp. Secy. | 10 Mar 2023 |
Insider Transactions Reported by Matthew Lang:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.